Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
7 High-Risk, High-Reward Small-Cap Stocks to Buy Now
09:18am, Friday, 13'th May 2022
Many small-cap stocks in the S&P 600 Small Cap Index aren't big names, but they have the change of bringing big rewards. The post 7 High-Risk, High-Reward Small-Cap Stocks to Buy Now appeared first on
WHO head censored in China after criticizing zero-COVID policy, and U.S. cases are now up 52% from two weeks ago
11:24am, Thursday, 12'th May 2022 MarketWatch
The head of the World Health Organization is being censored on China's internet after criticizing its zero-COVID policy for being unsustainable.
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 26, 2022 at 9:00am EDT
10:30am, Thursday, 12'th May 2022 GlobeNewswire Inc.
GAITHERSBURG, Md., May 12, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2022 Annual Meeting of Stockholders will be held in a virtual-only format via live
Emergent BioSolutions (EBS) Q1 2022 Earnings Call Transcript
10:30pm, Friday, 29'th Apr 2022 The Motley Fool
EBS earnings call for the period ending March 31, 2022.
Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates
06:25pm, Friday, 29'th Apr 2022 Zacks Investment Research
Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.
Why Emergent BioSolutions Stock Is Sinking Today
04:45pm, Friday, 29'th Apr 2022 The Motley Fool
The company's Q1 results were disappointing.
Emergent's (EBS) Q1 Earnings Miss, Revenues Beat Estimates
03:48pm, Friday, 29'th Apr 2022
Emergent's (EBS) first-quarter 2022 earnings miss estimates while sales beat the mark. EBS suspends its CDMO guidance for 2022 until it gets a better picture of the COVID-19 vaccine requirements.
Emergent BioSolutions Suspends CDMO Guidance As It Awaits Clarity On COVID-19 Vaccine Requirements
03:09pm, Friday, 29'th Apr 2022
Emergent BioSolutions Inc (NYSE: EBS) reported Q1 sales of $307.5 million, down 10% Y/Y, beating the consensus of $283 million. Total product sales increased 72% to $237.1 million, while Contract de
Emergent BioSolutions Inc. (EBS) CEO Bob Kramer on Q1 2022 Results - Earnings Call Transcript
09:47pm, Thursday, 28'th Apr 2022
Emergent BioSolutions Inc. (NYSE:EBS ) Q1 2022 Results Conference Call April 28, 2022 5:00 PM ET Company Participants Bob Burrows - VP, IR Bob Kramer - President and CEO Rich Lindahl - CFO Conference
Emergent Biosolutions (EBS) Q1 Earnings Lag Estimates
09:25pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25% and 3.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Q1 Earnings Lag Estimates
06:48pm, Thursday, 28'th Apr 2022
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -25% and 3.86%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for April 28th
12:18pm, Thursday, 28'th Apr 2022 Zacks Investment Research
LAZR, EBS, and ROCK have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2022
New Strong Sell Stocks for April 28th
09:49am, Thursday, 28'th Apr 2022
LAZR, EBS, and ROCK have been added to the Zacks Rank #5 (Strong Sell) List on April 28, 2022
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
06:03pm, Wednesday, 27'th Apr 2022 Zacks Investment Research
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
Drug/Biotech Stocks Q1 Earnings Due on Apr 28: MRK, LLY & More
03:18pm, Wednesday, 27'th Apr 2022
Let us look at the five biotech/pharma companies, slated to release quarterly results on Apr 28.
